Correlation between cognitive function and relapse of schizophrenia regarding dose reduction in patients undergoing high-dose antipsychotic therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220273

Enrollment

130

Registered

2017-01-12

Start date

2011-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

Intervention type:DRUG Name of intervention:dose reduction of antipsychotics Dose form / Japanese Medical Device Nomenclature:TABLET Route of administration / Site of application:ORAL Dose per adminis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inpatients with a diagnosis of schizophrenial, and those in the chronic phase receiving mean daily antipsychotic doses exceeding 1000-mg CPZ eq./day.

Exclusion criteria

Exclusion criteria: mental retardation, substance abuse or dependence, a history of major head trauma, serious medical or neurological disorders, or depot antipsychotic injections within the previous 3 months and electroconvulsive therapy within the previous 6 months

Design outcomes

Primary

Measure	Time frame
relapse by reduction of antipsychotics	—

Secondary

Measure	Time frame
cognitive function(digit span, vocabulary, block design)	—

Countries

Japan

Contacts

Public ContactRyota Ataniya

Okada hospital

ryotaataniya@pbt.nir.jp+81-4-7124-6151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026